title: IMPACT-CABG Trial: Implantation of CD133(+) Stem Cells in Patients Undergoing Coronary Bypass Surgery-Presentation of the First Treated Patient.
abstract: The IMPACT-CABG study is the first Canadian randomized-controlled phase II clinical trial aiming to assess the effect of intramyocardial (IM) injections of CD133(+)-selected stem cells in patients referred for coronary artery bypass graft (CABG) with a "chronic" myocardial infarction and persistent left ventricular dysfunction. Patients are followed for 2 years with different imaging techniques including the stress magnetic resonance to evaluate the global and regional myocardial viability. Before the beginning of the randomization, the 5 first patients are treated in an open-label fashion to assess safety and feasibility of the IM CD133(+) injections. Herein, we report the first Canadian patient treated with IM injection of CD133(+) cells during CABG surgery as part of the IMPACT-CABG trial.
authors.affiliation: Department of Cardiac Surgery, CHUM, 3840 Rue Saint-Urbain, Montréal, QC, Canada H2W 1T7 ; Surgery Department, Université de Montréal, Montréal, QC, Canada H3C 3J7.
authors.forename: Jessica
authors.initials: J
authors.lastname: Forcillo
authors.forename: Louis-Mathieu
authors.initials: LM
authors.lastname: Stevens
authors.forename: Samer
authors.initials: S
authors.lastname: Mansour
authors.forename: Ignacio
authors.initials: I
authors.lastname: Prieto
authors.forename: Denis-Claude
authors.initials: DC
authors.lastname: Roy
authors.forename: Nicolas
authors.initials: N
authors.lastname: Noiseux